Compare Amgen, Inc. (AMGN) vs InMode Ltd (INMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs InMode Ltd — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while InMode Ltd trades at $15.33 (market cap $878.88M). The key difference: Amgen, Inc. is far larger — about 223.1× InMode Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| AMGN | INMD | |
|---|---|---|
Market Cap | $196.12B | $878.88M |
Sector | Health | Technology |
52-Week High | $388.16 | $16.62 |
52-Week Low | $271.18 | $12.76 |
Enterprise Value | $241.41B | $346.55M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
INMD trades at $15.28, up 1.8% on the day, with a bullish technical signal from moving averages and oscillators. The company reported a Q1 2026 earnings miss but maintains strong profitability with a 23.27% net income margin. Recent news includes an unsolicited acquisition proposal from Steel Partners at $16.75 per share, alongside ongoing securities fraud investigations announced in early July 2026.
The stock presents a mixed outlook; the acquisition offer and solid fundamentals suggest upside near the $16.50 consensus target, but legal scrutiny and earnings volatility pose significant risks. Investor sentiment is divided, with analysts evenly split between Buy and Hold ratings, reflecting uncertainty around the company's near-term trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
